Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.56 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 9/20 | 0.50 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 5/20 | 0.42 |
| ▸ | HTR2B | P41595 | 5/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14085320 | 0.79 | LMNA (0.42) | PKN2HTR2CLMNAMAPTNISCH | |
| SCHEMBL4789087 | 0.79 | ADRA2A (0.59) | ADRA2AADRA2BHTR2AHTR2CHTR2B | |
| SCHEMBL30269982 | 0.78 | HTR2A (0.49) | ADRA2AADRA2BHTR2AHTR2CHTR2B | |
| SCHEMBL4790022 | 0.78 | HTR2A (0.49) | ADRA2AADRA2BHTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL9252509 | 0.78 | ADRA2A (0.58) | ADRA2AADRA2BHTR2AHTR2CHTR2B | |
| SCHEMBL8960144 | 0.76 | ADRA2A (0.61) | ADRA2AADRA2BHTR2AHTR2CHTR2B | |
| SCHEMBL28369710 | 0.76 | ADRA2A (0.47) | ADRA2AADRA2BHTR2AHTR2CHTR2B | |
| SCHEMBL29140051 | 0.76 | ADRA2A (0.61) | ADRA2AADRA2BHTR2AHTR2CHTR2B | |
| SCHEMBL8960083 | 0.76 | ADRA2A (0.61) | ADRA2AADRA2BHTR2AHTR2CHTR2B | |
| SCHEMBL8960049 | 0.76 | ADRA2A (0.61) | ADRA2AADRA2BHTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110818683-B | 2-pyridine substituted urea structure small molecule compound and synthesis and application thereof | 中国科学院上海药物研究所 | 2023-04-14 | — | — | CN | disclosed |
| CN-110818683-A | 2-pyridine substituted urea structure small molecule compound and synthesis and application thereof | 中国科学院上海药物研究所 | 2020-02-21 | — | — | CN | disclosed |
| WO-2008015271-A1 | PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THE USE AS A MEDICINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-07 | — | — | WO | disclosed |
| US-20080032998-A1 | Pyrazolopyrimidines, a process for their preparation and their use as medicine | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080032998-A1 | Pyrazolopyrimidines, a process for their preparation and their use as medicine | GRM5, GRM1, GRIK5 | ADRA2A 1504/4885ADRA2B 1119/4885HTR2A 421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.